Updates

Date: October 23, 2026 To, To, Corporate Relationship Department Listing Compliance Department BSE Limited National Stock Exchange of India Limited, Phiroze Jeejeebhoy Towers, 25th Floor, Exchange Plaza, 5th Floor, Plot No. C/2, G Block, Dalal Street, Mumbai – 400 001 Bandra Kurla Complex, Bandra (E), Mumbai-400051 Scrip Code: 531146 SYMBOL: MEDICAMEQ Subject: Outcome of the Meeting of Preferential Issue Committee of the Board of Directors of Medicamen Biotech Limited (“the Company”) in accordance with Regulation 30 of the Securities & Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015. Dear Sir/Ma’am, With reference to the captioned subject and in accordance with Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby inform you that the Preferential Issue Committee of the Board of Directors of Medicamen Biotech Limited (“the Company”) at their meeting held today i.e. October 23, 2026, has, inter alia, considered and approved the allotment of 5,00,000 Equity Shares pursuant to conversion of 5,00,000 Fully Convertible Warrants (“Warrants”) at an issue price of Rs. 530/- per equity share, for cash, for an aggregate amount of Rs. 26,50,00,000/- on a preferential basis, to the entity belonging to the ‘Promoter and Promoter Group’ category: S. No. Name of the proposed allottees Category No. of Equity Shares allottee 1. Shivalik Rasayan Limited Promoter & Promoter Group 5,00,000 Total 5,00,000 Consequent to the said allotment, the Paid-up Equity Share Capital of the Company stands increased to Rs. 14,06,28,150/- comprising of 1,40,62,815 Equity Shares of face value of Rs. 10/- each. The meeting of Preferential Issue Committee of the Board of Directors commenced at 11.00 AM and concluded at 11.45 AM This is for your information and records. Thanking You, Yours Faithfully, For Medicamen Biotech Limited Parul Choudhary Company Secretary & Compliance Officer